top of page
Cancer Blog
- Dr. Robert Nagourney -
Search


The Enormous Impact of EVA/PCD Chemosensitivity Testing in Patients with Rare Cancers: Durable Benefit Provided by An Unexpected Recommendation
The drug we recommended, Pazopanib, would not normally be expected to have activity in this rare and aggressive cancer.

Dr. Robert A. Nagourney, MD
Nov 32 min read


FOR STAGE 4 PANCREATIC CANCER, WHAT IS THE BEST TREATMENT?
The incidence of pancreatic cancer in the United States is increasing at an alarming rate. With 57,600 new diagnoses and 47,050 deaths in...

Dr. Robert A. Nagourney, MD
Feb 1, 20215 min read
bottom of page
